Report of Foreign Issuer (6-k)
May 22 2020 - 7:03AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
6-K
Report
of Foreign Private Issuer
Pursuant
to Rule 13a-16 or 15d-16
of the
Securities Exchange Act of 1934
For
the month of May 2020
Commission
File Number: 001-37643
KITOV
PHARMA LTD.
(Translation
of registrant’s name into English)
One
Azrieli Center, Round Tower,
132
Menachem Begin Road, Tel Aviv 6701101, Israel
(Address
of principal executive offices)
Indicate
by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.
Form
20-F ☒ Form 40-F ☐
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ____
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ____
Kitov
Pharma Ltd. (the “Company” or the “Registrant”) is announcing that on May 22, 2020, the Company issued
a press release, “Kitov Announces U.S. FDA Acceptance of Investigational New Drug Application to Conduct Phase 1/2 Clinical
Trial of NT219 in Multiple Types of Advanced Cancer Patients”, which is attached hereto as Exhibit 99.1.
This
Form 6-K, including all exhibits attached hereto, is hereby incorporated by reference
into each of the Registrant’s Registration Statements on Form F-3 filed with the Securities and Exchange Commission on December
12, 2016 (Registration file numbers 333-207117 and 333-211477), the Registrant’s Registration Statement on Form S-8 filed
with the Securities and Exchange Commission on May 20, 2016 (Registration file number 333-211478), the Registrant’s Registration
Statement on Form S-8 filed with the Securities and Exchange Commission on June 6, 2017 (Registration file number 333-218538),
the Registrant’s Registration Statement on Form F-3, as amended, originally filed with the Securities and Exchange Commission
on July 16, 2018 (Registration file number 333-226195), the Registrant’s Registration Statement on Form S-8 filed with the
Securities and Exchange Commission on March 28, 2019 (Registration file number 333-230584), the Registrant’s Registration
Statement on Form F-3 filed with the Securities and Exchange Commission on September 16, 2019 (Registration file number 333-233795),
the Registrant’s Registration Statement on Form F-3 filed with the Securities and Exchange Commission on December 2, 2019
(Registration file number 333-235327), the Registrant’s Registration Statement on Form F-3 filed with the Securities and
Exchange Commission on May 13, 2020 (Registration file number 333- 238229), and the Registrant’s Registration Statement
on Form S-8 filed with the Securities and Exchange Commission on May 28, 2020 (Registration file number 333-238481), to
be a part thereof from the date on which this report is submitted, to the extent not superseded by documents or reports subsequently
filed or furnished.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
|
KITOV
PHARMA LTD.
|
|
|
|
May
22, 2020
|
By:
|
/s/
Isaac Israel
|
|
|
Isaac
Israel
|
|
|
CEO
& Director
|
2
Kitov Pharma (NASDAQ:KTOV)
Historical Stock Chart
From Aug 2024 to Sep 2024
Kitov Pharma (NASDAQ:KTOV)
Historical Stock Chart
From Sep 2023 to Sep 2024